Гормональная терапия у женщин с миомой матки в пери- и постменопаузе: безопасно ли это? (Обзор литературы)
https://doi.org/10.33667/2078-5631-2019-2-14(389)-38-44
Аннотация
Менопаузальная гормональная терапия (МГТ) является эффективным методом лечения женщин в пери- и постменопаузе, хотя есть данные, что длительное использование гормональной терапии связано с незначительным повышением риска рака молочной железы, тромбоэмболии и инсульта. Данные обзора литературы, которые оценивают эффект МГТ на размер и объем бессимптомных миом матки у женщин в пери- и постменопаузе, противоречивы. Некоторые исследования связывают увеличение размеров ранее существующих и формирование новых миом с более высокими дозами прогестогенов в комбинированной (эстроген + прогестоген) терапии. Селективные модуляторы рецепторов эстрогена, обладающие тканеспецифическими эстрогенными агонистическими и антагонистическими эффектами, такие как ралоксифен, имеют благоприятный клинический профиль и могут быть вариантом лечения женщин с бессимптомными миомами матки.
Ключевые слова
Об авторе
Я. З. Зайдиева
ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии»
Россия
Россия
д. м. н., проф., рук. отделения гинекологической эндокринологии
г. Москва
Список литературы
1. World Health Technical Report Series. Research on the Menopause. Geneva, Switzerland: World Health Organization; 2015.
2. Menopause: A primer for the perimenopausal. North American Menopause Society. Available at: www.menopause.org/for-women/menopauseflashes/menopause-symptoms-and-treatments/menopause-101-a-primer-for-the-perimenopausal. Accessed February 10, 2018.
3. Santoro N. Perimenopause: from research to practice. J Womens Health (Larchmt) 2016; 25: 332–339.
4. Manson JE, Chlebowski RT, Stefanick ML, et al. The Women’s Health Initiative Hormone Therapy Trials: update and overview of health outcomes during the intervention and post-stopping phases. JAMA 2013; 310: 1353–1368.
5. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24: 728–753.
6. Manta L, Suciu N, Toader O, Purcrea R, Constantin A, Popa F. The etiopathogenesis of uterine fibromatosis. J Med Life 2016; 9: 39–45.
7. Moravek MB, Bulun SE. Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution. Curr Opin Obstet Gynecol 2015; 27: 276–283.
8. Plewka D, Marczynski J, Morek M, Bogunia E, Plewka A. Receptors of hypothalamic-pituitary-ovarian-axis hormone in uterine myomas. Biomed Res Int 2014; 2014: 521313.
9. Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch Toxicol 2012; 86: 1491–1504.
10. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009; 94: 545–551.
11. Sui Y-X, Sun C, Lv S-L, et al. Perineal leiomyoma in a postmenopausal woman: a case report. Oncol Lett 2016; 12: 2045–2047.
12. Tsai YM. A postmenopausal woman with sciatica from broad ligament leiomyoma: a case report. J Med Case Rep 2016; 10: 304.
13. Colacurci N, De Franciscis P, Cobellis L, Nazzaro G, De Placido G. Effects of hormone replacement therapy on postmenopausal uterine myoma. Maturitas 2000; 35: 167–173.
14. Yang C. H., J. N. Lee, S. C. Hsu, C. H. Kuo, E. M. Tsai. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women — a 3-year study. // Maturitas, 2002, Vol. 43, Issue 1, P. 35–39.
15. Idowu BM, Ibitoye BO, Adetiloye VA. Uterine artery Doppler velocimetry of uterine leiomyomas in Nigerian women. Rev Bras Ginecol Obstet 2017; 39: 464–470.
16. Palomba S, Sena T, Morelli M, Noia R, Zullo F, Mastrantonio P. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2002; 102: 199–201.
17. Polatti F, Viazzo F, Colleoni R, Nappi RE. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas 2000; 37: 27–32.
18. Huang KE, Baber R; Asia Pacific Tibolone Consensus Group. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric 2010; 13: 317–327.
19. Garefalakis M, Hickey M. Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence. Clin Interv Aging 2008; 3: 1–8.
20. Bundred NJ, Kenemans P, Yip CH, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res 2012; 14: R 13.
21. Gregoriou O, Vitoratos N, Papadias C, Konidaris S, Costomenos D, Chryssikopoulos A. Effect of tibolone on postmenopausal women with myomas. Maturitas 1997; 27: 187–191.
22. De Aloysio D, Altieri P, Penacchioni P, Salgarello M, Ventura V. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas 1998; 29: 261–264.
23. Fedele L, Bianchi S, Raffaelli R, Zanconato G. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol 2000; 88: 91–94.
24. Simsek T, Karakus C, Trak B. Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. Maturitas 2002; 42: 243–246.
25. An K-C. Selective estrogen receptor modulators. Asian Spine J 2016; 10: 787–791.
26. Del Pup L. Ospemifene: a safe treatment of vaginal atrophy. Eur Rev Med Pharmacol Sci 2016; 20: 3934–3944.
27. Johnson K, Hauck F. Conjugated estrogens/ bazedoxifene (Duavee) for menopausal symptoms. Am Fam Physician 2016; 93: 307–314.
28. Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 2013; 8: 135–155.
29. Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen- associated endometrial cancer (review). Oncol Lett 2015; 9: 1495–1501.
30. Kataria PSC, Kendre PP, Patel AA, Bohra MZ, Tahiliani N. Tamoxifen induced pancreatitis: an unusual complication of commonly used drug. J Clin Diagn Res 2017; 11: XD 05-XD 06.
31. Howe SR, Pass HI, Ethier SP, Matthews WJ, Walker C. Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen. Cancer Res 1996; 56: 4049–4055.
32. Fuchs-Young R, Howe S, Hale L, Miles R, Walker C. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog 1996; 17: 151–159.
33. Schwartz LB, Rutkowski N, Horan C, Nachtigall LE, Snyder J, Goldstein SR. Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation. J Ultrasound Med 1998; 17: 699–703.
34. Kang J, Baxi L, Heller D. Tamoxifen-induced growth of leiomyomas. A case report. J Reprod Med 1996; 41: 119–120.
35. Kimya Y, Cengiz C, Tolunay S. Endometrial polyps, cystic glandular hyperplasia and atypical leiomyoma associated with tamoxifen therapy. Int J Gynaecol Obstet 1994; 46: 69–70.
36. Um MJ, Cho EA, Jung H. Combination therapy of raloxifene and alendronate for treatment of osteoporosis in elderly women. J Menopausal Med 2017; 23: 56–62.
37. Faverani LP, Polo TOB, Ramalho-Ferreira G, et al. Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats. Clin Oral Investig 2018; 22: 255–265.
38. Porter KB, Tsibris JCM, Porter GW, et al. Tampa, Florida, and Indianapolis, Indiana–effects of raloxifene in a guinea pig model for leiomyomas. Am J Obstet Gynecol 2008; 179: 1283–1287.
39. Palomba S, Orio F Jr, Russo T, et al. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. Fertil Steril 2005; 84: 154–161.
40. Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004; 81: 132–136.
41. Srinivasan V., Martens M. G. Menopause: The Journal of The North American Menopause Society. 2018, Vol. 25, No. 8, pp. 1–9 by The North American Menopause Society.
42. EMAS position statement: Management of uterine fibroids. Pérez-López F.R., Ornat L., Ceausu I., Depypere H., Tamer Erel C., Lambrinoudaki I., Schenck-Gustafsson K., Simoncini T., Tremollieres F., Rees M. // Maturitas. — 2014. — Vol. 79. — Issue 1. — Р. 106–116.
43. Sener A. B., Seckin N. C., Ozmen S., Gökmen O., Doğu N., Ekici E. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril. 2006; 65: 354–357.
Рецензия
Для цитирования:
Зайдиева Я.З. Гормональная терапия у женщин с миомой матки в пери- и постменопаузе: безопасно ли это? (Обзор литературы). Медицинский алфавит. 2019;2(14):38-44. https://doi.org/10.33667/2078-5631-2019-2-14(389)-38-44
For citation:
Zaydieva Ya.Z. Hormone therapy in menopausal women with fibroids: is it safe? (Literature review). Medical alphabet. 2019;2(14):38-44. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-14(389)-38-44
Просмотров:
1571
Послать статью по эл. почте 